BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06163430 (TERN-701 in Relapsed/refractory Chronic Myeloid Leukemia): BVCT ex-ante prediction vs. reported outcome

On 24 Jul 2024, BioinvestGPT's BVCT predicted technical success and commercial partial success for this trial. The 3 Nov 2025 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically probably significant and commercially TBD.

Clinical Trial

NCTID
NCT06163430
Acronym
CARDINAL
Drug Name
TERN-701
Drug MoA
BCR ABL1 myristoyl-pocket-binding TKI inhibitor
Drug Modality
small molecule
Drug Class
Best-In-Class
Therapeutic Area
Neoplasms
Indication
Relapsed/refractory Chronic Myeloid Leukemia
Human Patients
100
Sponsor
Terns Pharmaceuticals
Phase
Phase 1

Prediction of , index 1697

Prospective Prediction
Prediction Index
1697
Prediction Date
Commercial Prediction
partial SUCCESS (commercially sufficient clinical benefit in CR non-superior non-inferior to ELVN001 for CML patients without T315I mutation) partial FAILURE (commercially insufficient clinical benefit in CR inferior to ELVN001 for CML patients with either T315I mutation or asciminib intolerance)
Technical Prediction
SUCCESS (statistically significant clinical benefit in CR)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
467 days in advance
Readout Data Interpretation
TERN701 achieved 64% MMR at week 24
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically probably significant and commercially TBD
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia
Phase
Phase 1, Phase 2
Status
Recruiting
Enrollment
180
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Conditions
Chronic Myeloid Leukemia, Chronic Phase; Chronic Myeloid Leukemia
Interventions
DRUG: TERN-701
Design
Randomized · Parallel · None
Primary purpose
Treatment
Start
2024-03-26
Primary completion
2029-11-30
Completion
2030-05-31
Primary outcomes
  • Part 1 - Incidence of Dose Limiting Toxicities during the first cycle of treatment (First cycle is 28 days)
  • Part 1 - Serious Adverse Events (up to 3 years)
  • Part 1 - Adverse Events (up to 3 years)
  • Part 2- Complete Hematologic Response (CHR) (up to 3 years)
  • Part 2: Molecular response (MR) (up to 3 years)

NCT06163430 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials